Morroniside ameliorates glucocorticoid-induced osteoporosis and promotes osteoblastogenesis by interacting with sodium-glucose cotransporter 2

• Published in: Pharmaceutical biology Vol. 61; no. 1; pp. 416 - 426
• Main Authors: Yang, Hou-Zhi, Dong, Runbei, Jia, Yutao, Li, Yuqiao, Luo, Gan, Li, Tianhao, Long, Yao, Liang, Shuang, Li, Shanshan, Jin, Xin, Sun, Tianwei
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2023; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Animals; Bone density; Bone loss; Cbfa-1 protein; Cell Differentiation; Cell Line; Cell proliferation; Cell viability; Danio rerio; Glucocorticoids; Glucocorticoids - toxicity; Glucose; glucose pockets; MC3T3-E1 cells; molecular docking; Molecular Docking Simulation; Osteoblastogenesis; Osteoblasts; Osteogenesis; Osteoporosis; Osteoporosis - chemically induced; Osteoporosis - drug therapy; Osteoporosis - prevention & control; SGLT2; Sodium - adverse effects; Sodium - metabolism; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 - adverse effects; Sodium-Glucose Transporter 2 - metabolism; Vertebrae; Zebrafish; glucose pockets; molecular docking; zebrafish; SGLT2; MC3T3-E1 cells

Morroniside (MOR) possesses antiosteoporosis (OP) effects, but its molecular target and relevant mechanisms remain unknown. We investigated the effects of MOR on glucocorticoid-induced OP and osteoblastogenesis and its underlying mechanisms. The effects of MOR (10-100 μM) on the proliferation and di...